Literature DB >> 3057692

Chronic injury of human renal microvessels with low-dose cyclosporine therapy.

B D Myers1, L Newton, C Boshkos, J A Macoviak, W H Frist, G C Derby, M G Perlroth, R K Sibley.   

Abstract

Physiologic and morphologic techniques were used to study kidneys of cardiac transplant recipients treated with either low-dose (low-CsA) or high-dose (high-CsA) cyclosporine. After 12 months both low-CsA (4.6 +/- 0.4) and high-CsA (6.3 +/- 0.3 mg/Kg/24 hr, p less than 0.01) were associated with azotemia and hypertension; GFR with each regimen was depressed below values in a third group treated without CsA (no-CsA) by 40-47%, while corresponding renal vascular resistance was elevated greater than 2-fold (P less than 0.01). Morphologic changes in both CsA groups included an obliterative arteriolopathy with downstream collapse or sclerosis of glomeruli. Determination of renal arcuate vein occlusion pressure revealed an increasing renal artery-to-peritubular capillary pressure gradient between 1 and 12 months of CsA therapy. Fractional clearances of dextrans of graded size were elevated at each time compared with the no-CsA group. Analysis of dextran transport with an isoporous membrane model indicates that transglomerular hydraulic pressure difference (delta P) approximated 39 with no-CsA, but was reduced with low-CsA therapy to about 30 at 1 month, and about 34 mmHg after 12 months. We conclude that chronic CsA therapy induces constriction and eventual occlusion of afferent arterioles, causing downstream glomerular damage that is irreversible. Low versus high dosage of CsA confers only marginal protection against this serious microvascular injury.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3057692     DOI: 10.1097/00007890-198811000-00014

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  17 in total

Review 1.  Emerging indications for the use of cyclosporin in organ transplantation and autoimmunity.

Authors:  P A Keown
Journal:  Drugs       Date:  1990-09       Impact factor: 9.546

2.  Transplantation.

Authors:  T E Starzl
Journal:  JAMA       Date:  1989-05-19       Impact factor: 56.272

Review 3.  Current status of renal transplantation.

Authors:  M G Suranyi; B M Hall
Journal:  West J Med       Date:  1990-06

4.  Cyclosporin A administration in dermatology: once a day or in fractional doses?

Authors:  M J Korstanje
Journal:  Arch Dermatol Res       Date:  1990       Impact factor: 3.017

5.  Tacrolimus (FK506)-Associated Renal Pathology.

Authors:  Parmjeet S Randhawa; Thomas E Starzl; Anthony Jake Demetris
Journal:  Adv Anat Pathol       Date:  1997-07       Impact factor: 3.875

Review 6.  The pathophysiology of Sandimmune (cyclosporine) in man and animals.

Authors:  J Mason
Journal:  Pediatr Nephrol       Date:  1990-09       Impact factor: 3.714

Review 7.  Antibody-targeted polymer-bound drugs.

Authors:  B Ríhová
Journal:  Folia Microbiol (Praha)       Date:  1995       Impact factor: 2.099

Review 8.  Renal dysfunction associated with liver transplantation.

Authors:  R M Jindal; I Popescu
Journal:  Postgrad Med J       Date:  1995-09       Impact factor: 2.401

Review 9.  Immunosuppressive therapy in older cardiac transplant patients.

Authors:  Arezu Zejnab Aliabadi; Andreas Oliver Zuckermann; Michael Grimm
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

10.  Nephrotoxicity of cyclosporine in humans: effect of cyclosporine on glomerular filtration and proximal tubular reabsorption.

Authors:  P Heering; P Schadewaldt; D Bach; B Grabensee
Journal:  Clin Investig       Date:  1993-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.